Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma

The role of TOR in autophagy regulation from yeast to plants and mammals

(2014) Sandra Díaz-Troya et al.   Autophagy

Akt-Mediated Regulation of Autophagy and Tumorigenesis Through Beclin 1 Phosphorylation

(2012) R. C. Wang et al.   SCIENCE

mTOR Inhibitors Synergize on Regression, Reversal of Gene Expression, and Autophagy in Hepatocellular Carcinoma

(2012) H. E. Thomas et al.   Science Translational Medicine

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

(2011) Andrew X. Zhu et al.   CANCER

Abstract 4498: Biological characterization of NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials

(2011) charles F. Voliva et al.   CANCER RESEARCH

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

(2011) Johanna C. Bendell et al.   JOURNAL OF CLINICAL ONCOLOGY

AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1

(2011) Joungmok Kim et al.   NATURE CELL BIOLOGY

Pilot study: rapamycin in advanced hepatocellular carcinoma

(2010) M. Schöniger-Hekele et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

NVP-BEZ235 as a New Therapeutic Option for Sarcomas

(2010) M. C. Manara et al.   CLINICAL CANCER RESEARCH

The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma

(2010) D. C. Cho et al.   CLINICAL CANCER RESEARCH

Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts

(2009) P Cao et al.   BRITISH JOURNAL OF CANCER

Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells

(2009) Peter W. Schlosshauer et al.   GYNECOLOGIC ONCOLOGY

Rapamycin delays tumor development in murine livers by inhibiting proliferation of hepatocytes with DNA damage

(2009) Laura Elisa Buitrago-Molina et al.   HEPATOLOGY

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo

(2009) Pippa Newell et al.   JOURNAL OF HEPATOLOGY

Direct control of mitochondrial function by mTOR

(2009) Arvind Ramanathan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

(2008) V. Serra et al.   CANCER RESEARCH

Control of autophagy by oncogenes and tumor suppressor genes

(2008) M C Maiuri et al.   CELL DEATH AND DIFFERENTIATION

Effect of Rapamycin Alone and in Combination with Sorafenib in an Orthotopic Model of Human Hepatocellular Carcinoma

(2008) Z. Wang et al.   CLINICAL CANCER RESEARCH

Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma

(2008) Augusto Villanueva et al.   GASTROENTEROLOGY

Diagnosis and Treatment of Hepatocellular Carcinoma

(2008) Hashem B. El-Serag et al.   GASTROENTEROLOGY

Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer

(2008) Magnus Rizell et al.   International Journal of Clinical Oncology

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE